Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, parallel multicenter study of use of remdesivir in patients with varying degrees of chronic renal impairment

Trial Profile

An open-label, parallel multicenter study of use of remdesivir in patients with varying degrees of chronic renal impairment

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; Ebola virus infections; Neurological disorders
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 08 Nov 2022 New trial record
  • 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top